Katuki (Picrorhiza kurroa): Liver Evidence, Conservation & Safety

TL;DR

Katuki (Picrorhiza kurroa) is a Himalayan herb whose rhizomes are an Ayurvedic remedy for jaundice. One 2-week RCT (n=33) in acute viral hepatitis found improved bilirubin and liver enzymes versus placebo. Larger, longer trials are lacking: and the plant is listed in CITES Appendix II with most demand met from wild collection; sustainability matters. Katuki is not a "detox."

What it is

Katuki (Picrorhiza kurroa Royle ex Benth., family Scrophulariaceae) is a small perennial herb native to the northwestern Himalayas, growing at altitudes of 3,000–5,000 meters (liver-disease plant review). The medicinal parts are the roots and rhizomes (Picrorhiza monograph). Its key active constituents are the iridoid glycosides picrosides I, II, and III plus kutkoside, known collectively as kutkin (Picrorhiza monograph).

Traditional use

Katuki is a well-established Ayurvedic treatment for jaundice (kamala) and other liver troubles, and has also been used for dyspepsia, bilious fever, chronic dysentery, bronchial complaints, and scorpion sting (Picrorhiza monograph). Its intense bitterness places it among Ayurveda's classic bitter tonics for pitta and kapha imbalances. These are traditional indications: what controlled studies have actually tested is covered below.

What modern research says

Acute viral hepatitis (randomized controlled trial)

The single most-cited human trial: a randomized, double-blind, placebo-controlled study of 33 patients with acute viral hepatitis gave 375 mg of Picrorhiza root powder three times daily for two weeks. Bilirubin, SGOT, and SGPT improved more favorably in the katuki group than in the placebo group (Vasisht et al., reported in the Alt Med Review monograph). The same trial is tabulated elsewhere as the katuki-alone arm (double-blind, 375 mg × 3, two weeks, n=15 treated of 33 enrolled) with no adverse drug reactions (clinical-trial review). This is the same study described above, not a second trial. Small, short, and unreplicated: promising, not proof.

Other clinical work (small and mostly combination formulas)

The same trial tabulation lists further small studies, nearly all testing katuki inside multi-herb formulas: Arogyavardhini (which contains katuki) in acute viral hepatitis (open-label n=24; double-blind n=20); Arogyavardhini with Triphala Guggulu in NAFLD (two arms, n=21, three months). And Katukyadi churna (katuki with nimba, amrita, bhringaraj, and bhumyamalaki) in NASH: a single-arm trial of 11 patients over 180 days, in which two participants had loose stools for the first eight days (clinical-trial review). Because these tested combinations, katuki-specific effects cannot be isolated from them.

Liver protection (animal studies)

In mice with chemically induced acute liver injury, a methanol extract of P. kurroa rhizome dose-dependently suppressed the rise in serum AST and ALT: the standard biochemical markers of liver damage (hepatoprotective-principles study). Related animal work covers toxin-induced (carbon tetrachloride, galactosamine, aflatoxin) and alcohol-related liver injury models (Picrorhiza monograph). Consistent and mechanistically interesting: but animal data, not human evidence.

What the evidence does not support

No adequate trial supports katuki as a liver "detox" or "cleanse": detoxification is not a measurable clinical endpoint. There are no robust trials for chronic liver disease, cirrhosis, or fatty liver as standalone katuki therapy. Acute viral hepatitis (a self-limiting illness in many patients) is not the same as chronic liver disease, and katuki is not a substitute for diagnosis, monitoring, or antiviral care where indicated.

Conservation status

Katuki's popularity has a cost: it is listed in CITES Appendix II, which regulates international trade through export permits: included at the June 1997 Conference of the Parties, effective September 18, 1997 (CITES listing document). A 2021 review reports that over 90% of market demand is met from wild collection, and that producing one kilogram of dried drug can require uprooting 300–400 individual plants: review-reported figures, not primary-source verified (comprehensive review). No current IUCN Red List assessment for the species was located during this review, so no IUCN category is stated here. If you use katuki, choose cultivated or certified sustainably sourced material.

Dosage

The only trial-tested regimen is 375 mg of root/rhizome powder three times daily for two weeks: the acute-hepatitis RCT dose, a research figure rather than a personal recommendation (Picrorhiza monograph). There is no established dose for any other use, and classical dose figures vary by formulation. Do not self-dose for liver disease.

Safety & contraindications

In the small published trials, no adverse drug reactions were reported for katuki; the main tolerability signal was loose stools in two of eleven NASH-trial participants taking a katuki-containing formula (clinical-trial review). Long-term human safety data do not exist. Jaundice and abnormal liver tests have many possible causes, viral hepatitis, bile obstruction, drug injury, autoimmune disease, that require medical evaluation; katuki should never delay diagnosis. There are no adequate data on use in pregnancy or breastfeeding: avoid unless a qualified practitioner advises otherwise.

FAQs

Does katuki detox the liver?

No: "liver detox" is a marketing phrase, not a measurable clinical outcome. Katuki has one small RCT in acute viral hepatitis and preclinical hepatoprotective data; there are no trials supporting a general detox or cleanse effect (clinical-trial review).

What did the hepatitis trial actually find?

In 33 patients with acute viral hepatitis, 375 mg of katuki root powder three times daily for two weeks improved bilirubin, SGOT, and SGPT more than placebo in a double-blind RCT (Picrorhiza monograph). It was small, short, and has not been replicated.

Is katuki endangered?

It is listed in CITES Appendix II, which controls international trade through export permits: included in 1997, effective September 18 of that year (CITES listing document). A 2021 review reports over 90% of market demand is met from wild collection; no current IUCN Red List assessment was located, so no IUCN category is stated here. Prefer cultivated or certified sustainable sources.

What is the dose of katuki?

The only trial-tested dose is 375 mg of root powder three times daily for two weeks (a research regimen, not a recommendation). No established dose exists for other uses (Picrorhiza monograph).

Is katuki safe?

Small trials reported no adverse drug reactions, with loose stools in a few participants on a katuki-containing formula: but these trials were tiny and short, and long-term human safety is unstudied (clinical-trial review). Liver symptoms need medical evaluation first.

Sources

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.